Sq cancer is of uncertain significance and warrants further research into new potential applications for HER2 targeting.

Disclosure of Interest None Declared

PTU-158 DNA PLOIDY ABNORMALITIES CORRELATE WITH INCREASING DEGREE OF DYSPLASIA IN CASES REFERRED TO A SPECIALIST CLINICAL IMAGE CYTOMETRY SERVICE FOR THE MANAGEMENT OF BARRETT'S OESOPHAGUS

doi:10.1136/gutjnl-2013-304907.248

¹D Oukrif, ^{2,3}M A Butt, ²E S Bloom, ^{2,3}R J Haidry, ²S-U-R Khan, ^{2,3}J Louis-Auguste, ³V Eneh, ¹M Rodriguez-Justo, ^{2,3}M R Banks, ¹M Novelli, ^{2,3}L B Lovat. ¹Pathology, UCH; ²NMLC, UCL; ³GI services, UCH, London, UK

Introduction In Barrett's oesophagus (BE), Barrett's dysplasia and esophageal carcinoma (EC) there can be genomic instability. This instability leads to DNA abnormalities, typically aneuploidy, where cells accumulate abnormal amounts of DNA. Tetraploidy is a specific term given to cells with twice the normal (diploid) content of DNA. In our specialist referral centre for BE, ploidy assessment is requested for cases with persistent or recurrent low-grade/indefinite for dysplasia (LGD/IFD), clinical suspicion of progression due for example to a strong family history of EC in long segment BE, or cases suspected to relapse after prior treatment for high-grade dysplasia/intramucosal cancer (HGD/IMC). This study aimed to assess correlation between dysplasia and DNA ploidy abnormalities (DNA-PA) in clinical cases with BE referred for ploidy assessment to the UCLH specialist image cytometry (IC) service.

Methods All clinical referrals for IC were retrospectively identified (n = 189) and reports from analysed blocks captured (n = 682). All samples were processed by a specialist IC technician to produce ploidy results with an automated image cytometric analyser. Ploidy histograms were then reviewed to confirm the automated IC result as diploid, aneuploid, tetraploid or equivocal. Histology was then reported or reviewed by an expert GI pathologist and scored as 1 (BE), 2 (IFD), 3 (LGD) or 4 (HGD).

Results Case referrals were received from 4 institutions, mean age was 58yo (24–85yo, SD 13) and the majority were men (79.9%). Corresponding histology was available in 69.7% (n = 475) of samples processed. DNA-PA positivity rates (Aneuploidy/Tetraploidy) in the sub-group with histology were 4% in BE (n = 376), 6.9% in IFD (n = 29), 29% in LGD (n = 31) and 51.3% in HGD (n = 39). Pearson product-moment correlation coefficient showed significant correlation between increasing degree of dysplasia and DNA-PA (Pearson r = 0.96, p = 0.039).

Abstract PTU-158 Figure

Conclusion This study has demonstrated that in our large case series DNA-PA's correlate with increasing degree of dysplasia. DNA-PA is a validated biomarker for cancer progression and has been used in our cohort to guide frequency of surveillance and in some LGD cases minimally invasive endoscopic therapy, where they otherwise would not have received it. Further longitudinal studies on the progression to cancer in our case series will provide further insight into this important biomarker.

Disclosure of Interest None Declared

PTU-159 CHARACTERISATION OF OESOPHAGEAL MUC1 EXPRESSION IN THE PROGRESSION TO OESOPHAGEAL ADENOCARCINOMA

doi:10.1136/gutjnl-2013-304907.249

^{1,2}M A Butt, ³D Oukrif, ^{1,2}R J Haidry, ⁴M Rashid, ¹S-U-R Khan, ¹H Pye, ¹E S Bloom, ⁵M Deonarain, ⁶D Swallow, ^{1,2}M R Banks, ³M Rodriguez-Justo, ³M Novelli, ^{1,2}L B Lovat. ¹NMLC, UCL; ²GI services; ³Pathology, UCH; ⁴Oncology, UCL; ⁵PhotoBiotics Ltd, ICL; ⁶Genetics, UCL, London, UK

Introduction Studies on oesophageal MUC1 expression have shown conflicting results. One found MUC1 in 100% of 52 oesophageal adenocarcinoma (OA) patient's using an anti-MUC1 antibody(1), whilst another found no expression in 23 OA cases at the RNA level(2). It is probable that detection of MUC1 repeat domains varies in the progression to cancer due to changes in glycosylation. This study aims to characterise oesophageal MUC1 expression using antibodies binding extracellular peptide repeats and an intracellular epitope unaffected by surface glycosylation.

Methods 138 paraffin embedded specimens were selected from 106 patients containing normal squamous (Sq; n = 34), normal gastric (G; n = 15), non-dysplastic Barrett's (NDBE; n = 27), low grade dysplasia (LGD; n = 22), carcinoma in-situ (HGD/IMC; n = 35) and invasive OA (IOA; n = 21). 11 IOA cases had matched specimens containing infiltrated lymph nodes (LN). Immunohistochemistry was performed using the antibodies CT2 (binding the MUC1 cytoplasmic tail)(3), NCL-MUC-1(binding the epitope PDTRFAP of the extracellular peptide) and HuHMFG1 (binding PDTR of the extracellular peptide). Intensity (0 to 3+) and extent (0; < 1% = 1; 1–10% = 2; 10–33% = 3; 33–66% = 4; > 66% = 5) of tissue staining was scored. Positive cases were defined as those staining 2+/3+ in > 10% of the pathology examined.

Abstract PTU-159 Figure

Results MUC1 was shown to be significantly expressed using our antibody panel (HuHMFG1; CT2; NCL-MUC-1) in Sq (61%; 38%; 40%), G (100%; 100%; 86%), NDBE (96%; 100%; 6%), LGD (91%; 86%; 12%), HGD/IMC (91%; 97%; 19%) and IOA (95%; 91%; 82%). 100% of the metastatic OA group with infiltrated LNs stained

positively with HuHMFG1. Using internal MUC1 detection with CT2 for comparison, the sensitivity & positive predictive value for external MUC1 detection were 95%; 95% for HuHMFG1 and 40%; 93% for NCL-MUC-1.

Conclusion This study suggests MUC1 expression inferred by detection with HuHMFG1 and CT2, binding extra and intracellularly, increases early in progression to OA. The MUC1 epitope bound by NCL-MUC-1 appears later. This may be due to changes in glycosylation during progression. Therapeutic modalities targeting MUC1 may be applicable to the majority of patients with preneoplastic BE and OA.

Disclosure of Interest None Declared

REFERENCES

1. Piessen *et al.* J. Clin. Pathol. 62, 1144–1146.
2. Guillem *et al.* Int. J. Cancer 88, 856–861.
3. Courtesy of Prof. Sandra Gendler. Mayo clinic. USA.

PTU-160 SECOND GENERATION PHOTOSENSITISER BASED PHOTODYNAMIC THERAPY IS EFFICACIOUS AND PENETRATES TISSUE MORE DEEPLY THAN RADIOFREQUENCY AND CRYO- ABLATIVE THERAPIES, OFFERING POTENTIAL FOR MORE INVASIVE GASTROINTESTINAL CANCERS

doi:10.1136/gutjnl-2013-304907.250

¹M A Butt, ¹E S Bloom, ²I Stamati, ¹R J Haidry, ³D Oukrif, ¹S-U-R Khan, ¹H Pye, ²M Deonarain, ²G Yahioglu, ¹L B Lovat. ¹National Medical Laser Centre, University College London; ²PhotoBiotics Ltd, Imperial College London; ³Research Department of Pathology, University College London, London, UK

Introduction Photodynamic therapy (PDT) has been used to both treat gastrointestinal (GI) cancers and for palliation. PDT has been limited by poor penetration of the laser light used to activate it. In recent years, PDT has been replaced by other minimally invasive modalities such as radiofrequency- and cryo-ablation due to fewer side effects. However, these are limited to superficial cancers. Activation of 2nd generation photosensitisers (PS) such as Talaporfin by light in the near infrared enables deeper tumour penetration. Talaporfin is undergoing clinical trials in the US with encouraging data from phase 1 studies in oesophageal and biliary cancers. This study aimed to compare the potency of several other PS's activated in the near infrared for GI tumours.

Methods The cytotoxic efficacy of five chlorin based PS's were evaluated against human oesophageal (OE19) and colon (HT29) cancer cell lines using a 670nm cold laser. Equivalent concentrations of PS were compared in the presence or absence of laser "light" activation. Power was set intentionally low at 0.33J/cm² to highlight the efficacy of the PS's. Cell viability was measured with standard MTT assay and the plates read on an Elisa plate reader at 490nm. The concentrations required to kill 50% of cells (IC₅₀) were calculated, and the dose response curves in light and dark compared using linear regression analysis and F tests to show selectivity to those cells exposed to near infrared light.

Results Cell viability counts in all plates were initially corrected for the untreated cell survival controls in the plate itself and then plotted on a log scale to produce dose response curves. This confirmed significantly cytotoxic efficacy in light vs dark for the PS's PPa (p = 0.001, IC₅₀ = 4.82 µM), PS1 (p = 0.03, IC₅₀ = 24.8 µM) and CE6 (p = 0.001, IC₅₀ = 75.8 µM) against OE19 cells, and PPa (p = 0.01, IC₅₀ = 3.8 µM), PS4 (p = 0.02, IC₅₀ = 4.5 µM) and CE6 (p = 0.0004, IC₅₀ = 26.1 µM) against HT29 cells.

Conclusion This study has shown these second generation chlorin-based photosensitisers to be effective against GI tract cancer cell lines. By virtue of being activated in the near infrared, they further offer deeper tissue penetration when compared with Porfimer sodium which is excited at 630 nm. Further quality control to GMP

standards and evaluation in-vivo is required before these PS can be used. However when translated, they may provide more effective PDT in the clinic than current minimally invasive strategies for GI cancers, and offer therapy to more deeply infiltrating tumours.

Disclosure of Interest None Declared.

PTU-161 EXPRESSION OF POLO-LIKE KINASE 1 AND GEMININ IS UP-REGULATED IN THE SQUAMOUS-METAPLASIA-DYSPLASIA-CARCINOMA SEQUENCE AND CORRELATES WITH ANEUPLOIDY

doi:10.1136/gutjnl-2013-304907.251

^{1,2}M A Butt, ^{1,2}R J Haidry, ³D Oukrif, ⁴J Dunn, ¹E S Bloom, ^{1,2}J Louis-Auguste, ²N Butter, ¹S-U-R Khan, ¹V Sehgal, ^{1,2}M R Banks, ³M Rodriguez-Justo, ^{1,2}L B Lovat, ³M Novelli. ¹NMCL, UCL; ²GI services; ³Pathology, UCH, London, UK; ⁴IMI, Oslo University, Oslo, Norway

Introduction Population based studies have shown a small but significant proportion of patients with Barrett's oesophagus (BE) progress to oesophageal adenocarcinoma (OA). Predicting which patients progress is of vital importance for risk stratification into increased surveillance regimes or early therapeutic intervention. We have previously shown the replication licensing factors (RLF) such as polo-like kinase-1 (PLK1) may act as surrogate markers of DNA ploidy abnormalities (DNA-PA) (1) and subsequent risk of progression to OAC. This study aimed to assess whether the RLF's are up-regulated in the metaplasia-dysplasia-carcinoma sequence independently of DNA-PA.

Methods Paraffin embedded oesophageal specimens were selected from 94 patients, and pathology grade (PG) scored as 1 (squamous = Sq; n = 4), 2 (non-dysplastic BE = NDBE; n = 19), 3 (low grade dysplasia = LGD; n = 20), 4 (carcinoma in-situ = HGD/IMC; n = 36) and 5 (invasive OA = IOA; n = 15). Sections were immunostained with the antibodies PLK1-M, PLK1-L and Gem using the automated BOND-MAX system (Leica). Intensity (I) (0 to 3+) and extent (E) (0; < 1% = 1; 1–10% = 2; 10–33% = 3; 33–66% = 4; > 66% = 5) of staining were scored by 2 expert GI pathologists, and mean scores calculated. DNA-PA was assessed using image cytometry (IC). Pearson r coefficient and two-tailed P values were calculated for correlations and significance.

Results A significant correlation with extent (r = 0.87, p = 0.05; r = 0.91, p = 0.03; r = 0.99, p = 0.0008) was seen with all RLFs (PLK1-M; PLK1-L; Gem). Only PLK1-M correlated with intensity (r = 0.92, p = 0.03) and total (I+E) scores (r = 0.91, p = 0.03). Aneuploidy was present in NDBE (6%), LGD (25%), HGD/IMC (61%) and IOA (67%). The proportion of aneuploid cases/group correlated significantly with PG (r = 0.97, p = 0.007) and mean I, E and total scores for PLK1-M (r = 0.97, p = 0.008; r = 0.96, p = 0.008; r = 0.98, p = 0.96).

Conclusion All assessed RLFs were found to be significantly up-regulated in the progression to OA, with geminin scoring highest when evaluated by extent scores. Overall PLK1-M appeared the best antibody, showing additional correlation with its intensity and total staining scores with PG and DNA-PA. We further demonstrated that aneuploidy still correlates with PG as we have previously reported. In future, PLK1-M and aneuploidy may provide the basis of a biomarker panel to help guide screening and therapy for those predicted to be at increased risk of progression to OA.

Disclosure of Interest None Declared

REFERENCE

1. Butt MA *et al.* Gut 2012; 61:Suppl 2 A302

PTU-162 OESOPHAGEAL MUCOSAL DILATED INTERCELLULAR SPACES (DIS), TRANSEPIHELIAL ELECTRICAL RESISTANCE AND PERCEPTION OF HEARTBURN

doi:10.1136/gutjnl-2013-304907.252

¹P Woodland, ¹C Lee, ¹D Sifrim. ¹Barts & The London School of Medicine, Queen Mary University of London, London, UK